Skip to content
Review Open access

Glaucoma neurodegeneration: targeted modulation of intraocular immune pathways – a review of novel therapeutic advances

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 122 references
Medicine

TL;DR

This review systematically examines the research progress on key intraocular immune pathways in glaucomatous neurodegeneration, with a primary focus on immune-inflammatory responses mediated by microglia, astrocytes, and T cells.

Abstract

Glaucoma is the leading global cause of irreversible blindness, with its pathogenesis extending far beyond elevated intraocular pressure. Dysregulation of the intraocular immune system plays a central role in the progressive death of retinal ganglion cells. This review systematically examines the research progress on key intraocular immune pathways in glaucomatous neurodegeneration, with a primary focus on immune-inflammatory responses mediated by microglia, astrocytes, and T cells. It delves into the molecular mechanisms of various immunoregulatory networks, including the TLR4/nuclear factor kappa B (TLR4/NF-κB), Janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK), complement, and T-cell receptor signaling pathways. The review analyzes potential therapeutic strategies targeting these pathways. By integrating the latest evidence from basic research and translational medicine, this article aims to provide a theoretical foundation and directional guidance for developing neuroprotective immunomodulatory therapies that go beyond intraocular pressure reduction.

Read PDF

Similar papers

Review Open access Sep 2026

Bridging Mechanism and Therapy in Ocular Disease: Mitochondrial, Vascular, and Immune Pathways in the Eye

There is an increasing global burden of ocular disorders, with an estimated 43.3 million people worldwide currently blind and a further 295 million living with moderate-to-severe vision impairment, driven by a complex pathogenesis that involves multiple cascade failures ranging from mitochondrial dysfunction to chronic...

S. Tejeda, Sese-Owei Ekaye, Jean M. Taylor et al. · 0 citations
Review Open access Sep 2026

Genetic susceptibility and neuroprotective gene therapy of normal tension glaucoma: a review

Normal-tension glaucoma (NTG) is a distinct form of glaucomatous optic neuropathy characterized by progressive retinal ganglion cell (RGC) degeneration and visual field loss despite intraocular pressure (IOP) remaining within the statistically normal range. Although IOP reduction remains the only established disease-mo...

Xiao-Yu Liu, Da-Dong Jia, Hao Hu et al. · 0 citations
Review Open access Oct 2026

Microglia in retinal vascular diseases: inflammatory mechanism and therapeutic target.

A review examines the role of microglia in RVDs and their potential as therapeutic targets, exploring strategies such as inhibiting microglial activation, regulating pro-angiogenic factor secretion, and targeting specific signaling pathways.

Jing Xu, Huan-Hui Yang, Kai-Ming Chen et al. · 0 citations
Review Open access Sep 2026

Ferroptosis in retinal neurodegeneration: mechanistic vulnerability, therapeutic targeting, and translational barriers

Current evidence supporting ferroptosis-related vulnerability in retinal neurodegenerative diseases is synthesized and emerging enabling strategies are evaluated, including nanocarrier-based delivery, long-acting gene modulation, and biomarker frameworks integrating ocular fluids, imaging, multi-omics, and artificial i...

Guang-Guang Wu, Su-Yu Wang, Zi-Yi Chen et al. · 0 citations
Review Open access Oct 2026

Molecular Mechanisms and Therapeutic Potential of Natural Neuroprotective Compounds in Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic inflammatory disease of the Central Nervous System characterized by immune-mediated demyelination, axonal damage, and progressive neurodegeneration, which critically contributes to irreversible disability. Currently, disease-modifying therapies are effective in treating inflammatory...

Greta Paolilli Treonze, Erjola Bej, M. Catanesi et al. · 0 citations
Nov 2026

Small-Molecule Drugs for Glaucoma: IOP-Lowering, Neuroprotective and Multi-Target Strategies

Glaucoma, a leading cause of irreversible blindness worldwide, is primarily driven by elevated intraocular pressure (IOP) and retinal ganglion cell (RGC) apoptosis. Small-molecule agents, owing to their high target specificity and excellent ocular tissue penetration, remain the cornerstone of clinical management. Thi...

Jun-Jie Wu, Lu Yu, Yin-Ping Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.